Patent · US Active

6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor

US8450321B2 · kind B2 · utility

45Cited by

12References

2Claims

0Family size

Assignee

GILEAD CONNECTICUT, INC. · US

Inventors

Scott A. Mitchell · East Haven, US
Kevin S. Currie · North Branford, US

Key dates

Filing date	Apr 6, 2012
Grant date	May 28, 2013
Priority date	—
Expiry date	Apr 6, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An imidazopyrazine having the structureor a pharmaceutically acceptable salt thereof, and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.